Ocular Delivery of peptides and proteins

Ocular Delivery of peptides and proteins

OCULAR DELIVERY OF PEPTIDES AND PROTEINS RICHARD ADDO, R.Ph., Ph.D ASSOCIATE PROFESSOR UNION UNIVERSITY SCHOOL OF PHARMACY JACKSON TENNESSEE USA OUTLINE Structure of eye and different pathways of ocular administration Challenges for ocular delivery of proteins/peptides Formulation considerations Peptide transport systems in the eye Ocular administration for topical delivery of proteins/peptides Ocular administration for systemic delivery of proteins/peptides Strategies for ocular delivery of proteins/peptides

STRUCTURE OF THE EYE Outermost coat: Clear, transparent cornea and white, opaque sclera Middle layer: iris anteriorly, choroid posteriorly and intermediate ciliary body Inner layer: retina A. Topical administration with trans-corneal permeation B. Topical administration with non-corneal permeation across the conjunctiva and sclera C. Drug distribution from the blood through the blood- aqueous barrier into the anterior chamber

D. Drug distribution from the blood-retina barrier into the posterior chamber E. Intra-vitreal drug administration route F. Sub-tenon injection BARRIERS TO ABSORPTION Basal layer, 2-3 layers of wing cells and 1-2 outermost layers of squamous cells Outermost layers Intercellular tight junctions surround the most superficial layers and restrict passage of peptides and proteins Absorption relies on transcellular passage or strategies that can modulate the tight junctions

Wing cells and basal cells Intercellular spaces are wider and permit paracellular diffusion Negatively charged corneal epithelium offers greater resistance to negatively charged compounds as compared to positively charged ones CHALLENGES TO OCULAR DELIVERY OF PROTEINS/PEPTIDES Barriers for locally delivered drugs Loss of drug from ocular surface Lacrimal-fluid barrier Blood-ocular barrier

Low drug contact time Tear production and turnover Consequent dilution Schematic presentation of the different barriers for ocular delivery of proteins and peptides FORMULATION CONSIDERATIONS Aggregation Is induced by shaking, prolonged storage, heating, freezing, lyophilization Can lead to Reduced bioactivity

Immunogenic reactions Blockage of tubing, membranes or pumps in an infusion set Unacceptable physical appearance such as opalescence Example: Insulin can undergo self-association/aggregation due to the hydrophobic regions of the molecule

Human epidermal growth factor (hEGF) undergoes pH and concentration dependent aggregation Can be prevented by Use of appropriate formulation excipients; example: mannitol, trehalose Proper care in processing of formulation Synthesizing a resistant derivative FORMULATION CONSIDERATIONS

Formulation Additives Protease Inhibitors: Used if the protein/peptide is likely to degrade upon ocular administration Aminopeptidase inhibitors: bestatin, amastatin, puromycin, p-chloromercuribenzoate Sugars: Exert a protective effect on proteins by changing the solvent structure around the protein Cyclodextrins: Act by molecular encapsulation of amino acid chains thereby preventing hydrophobic interactions PEPTIDE TRANSPORT SYSTEMS IN EYE Epithelial cells express nutrient transporters and receptors on their surface which help the movement of vitamins and amino acids across cell

membranes Proton coupled receptors help translocation of di- and tripeptides across the epithelium Transporters are classified as PepT1, PepT2 and peptide/histidine transporters (PHT1 and PHT2) Expression of PHT1 in bovine and human retinal pigment epithelial cells (BRPE and HRPE), ARPE19 cells (human RPE cell type), bovine and human neural retina cells has been reported PepT2 and PHT 2 expression reported in bovine and human retina Drugs with poor ocular bioavailability can be suitably modified by design to facilitate

recognition and uptake by peptide transporters MODES OF OCULAR DRUG ADMINISTRATION OCULAR ADMINISTRATION FOR TOPICAL DELIVERY Topical delivery is considered to be the best option for treatment of most ocular disorders Several peptides have been identified for treatment of ocular disorders like dry eye disease, age related macular degeneration, proliferative diabetic retinopathy, etc. Loss to systemic circulation must be minimized Phenylephrine used as a vasoconstrictor to minimize systemic absorption Use of mucoadhesive polymer to improve ocular absorption

Adverse physicochemical properties or enzymatic degradation of peptides might render them less effective Loading them in a carrier system like liposome or nanoparticle may limit some of these problems OCULAR ADMINISTRATION FOR TOPICAL DELIVERY Growth Factors Human Epidermal Growth Factor (hEGF) stimulates cell proliferation in the corneal epithelium thus causing epithelialization during wound healing

EGF can be produced biotechnologically in a commercially feasible manner It can thus be a suitable therapeutic agent for corneal trauma and during intraocular surgery Tissue Plasminogen Activator tPA can be used to achieve clot lysis after surgery for cataract and/or glaucoma Since tPA is present in aqueous humor and other ocular tissues, its use is like a supplementation of body

function Cyclosporin A It has immunosuppressive, anti-fungal and anti-inflammatory activity Primary use is inhibition of kidney graft rejection Instillation in eye can inhibit rejection of corneal grafts STUDIES SHOWING OCULAR DELIVERY OF EGF EGF Incorporated in Cationized Gelatin Hydrogel

EGF Incorporated in Beta Cyclodextrin Complex Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing, Hori K, Sotozono C, Hamuro J, Yamasaki K, Kimura Y, Ozeki M, Tabata Y, Kinoshita S, J Control Release. 2007 Apr 2;118(2):169-76. rhEGF/HP-beta-CD complex in poloxamer gel for ophthalmic delivery, Kim EY, Gao ZG, Park JS, Li H, Han K, Int J Pharm. 2002 Feb 21;233(1-2):159-67. OCULAR DELIVERY OF GANCICLOVIR In vitro transcorneal permeation Concentration in aqueous humor after instillation in rabbit eye

Preparation and ocular pharmacokinetics of ganciclovir liposomes, Yan Shen, Jiasheng Tu, AAPS J. OCULAR ADMINISTRATION FOR SYSTEMIC DELIVERY Occurs because of contact of instilled solution with conjunctival and nasal mucosae Advantages: Relative ease and low cost of formulating and administering eye drops (compared to injections) Relative insensitivity of eye towards immunological reactions (compared to lung and gut)

Absence of first pass metabolism Challenges: Reproducible delivery Low bioavailability OCULAR ADMINISTRATION FOR SYSTEMIC DELIVERY Insulin: When administered to the eye, a sustained lowering of blood glucose was observed Use of absorption enhancers may often be

required to enhance absorption of peptides through the eye Absorption enhancers must be safe and non- irritating to the eye Order of efficacy: Saponin>Fusidic Acid>BL-9 = EDTA>Glycocholate>Decamethonium=Tween 20 Aminopeptidase inhibitors or peptide analogs that are resistant to enzymes also help to improve bioavailability Systemic absorption of insulin ( SEM; n=5) following the ocular instillation of a 0.25% insulin solution containing Brij-78 as an enhancer. Data generated

following a b.i.d. administration of eyedrops over a three-month period ( - blood insulin concentration; o EFFECT OF ABSORPTION ENHANCER (BRIJ 78) ON SYSTEMIC DELIVERY OF INSULIN FROM AN OCULAR INSERT DEVICE Effect of Brij-78 on systemic delivery of insulin from an ocular device, Lee YC, Simamora P, Yalkowsky SH, J Pharm Sci. 1997 Apr;86(4):430-3. OCULAR ADMINISTRATION FOR SYSTEMIC DELIVERY Glucagon Used in treatment of hypoglycemia Can be delivered by the ocular route and has been reported to increase blood glucose Mol wt. is lower than insulin; may not need absorption enhancers

Calcitonin Long term administration required for treatment of hypercalcemia Besides the ocular route, other alternative routes like nasal, rectal, transdermal have also been explored TRANS-SCLERAL DELIVERY OF IgG TO THE RETINA ery of Bioactive Protein to the Choroid and Retina, Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP, Invest Ophthalmol Vis Sci. 2000 STRATEGIES FOR THE OCULAR DELIVERY OF PROTEINS/PEPTIDES Prodrugs Change physicochemical properties of a drug to improve permeation across cornea and enhance bioavailability First prodrug for ocular delivery: Dipivefrin, prodrug of

epinephrine used to treat glaucoma Desirable properties Good stability High enzyme lability Most common barriers that can be overcome are A low aqueous solubility, which prevents the development of aqueous eyedrops A low lipid solubility, which results in low corneal permeation and low ophthalmic bioavailability A short duration of action due to rapid drug elimination from site of action Systemic side-effects, due to low corneal and high systemic

absorption STRATEGIES FOR THE OCULAR DELIVERY OF PROTEINS/PEPTIDES Mucoadhesive Particulate Carriers Cornea and conjunctiva have a net negative charge Cationic polymers help to increase the concentration and residence time of polymer-associated drug

Chitosan biocompatible, biodegradable, enhances the paracellular transport of drugs Conventional eye drops Anionic or polyanionic Cationic or polycationic Zeta potential (mV)

Effect of Chitosan on Zeta Potential of Microparticles 40 30 20 10 0 -10 -20 -30 -40 -50 washout BSA

BSA+CSN Electrostatic Repulsion Electrostatic Attraction DELIVERY MECHANISM OF CATIONIC NANOPARTICLES Electrostatic interaction leading to Retention at the surface Reservoir effect in : Cornea Conjunctiva Transcorneal Route Diffusion via the scleral route

Sustained release to the retina CHITOSAN NANOPARTICLES FOR CYCLOSPORIN A DELIVERY Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A, De Campos AM, Snchez A, Alonso MJ. Int J Pharm. 2001 Aug 14;224(1-2):159-68 STRATEGIES FOR THE OCULAR DELIVERY OF PROTEINS/PEPTIDES Hydrogel Delivery Systems Allows slow release of drug from a hydrogel inserted beneath the eyelid Ocusert: First such device o Non-erodible ocular insert o Pilocarpine alginate core sandwiched between two

transparent, rate controlling membranes PLGA MICROSPHERES FOR DELIVERY OF VANCOMYCIN PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies, Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P, Eur J Pharm Biopharm. 2004 Mar;57(2):207-12 STRATEGIES FOR THE OCULAR DELIVERY OF PROTEINS/PEPTIDES Absorption Enhancers Promote penetration of drugs through corneal barrier by changing integrity of epithelial cell layer Examples: EDTA, sodium glycocholate and related cholates, tween-20, saponin Miscellaneous Approaches Cell penetrating peptides: TAT (Trans-activating transcription factor from

human immunodeficiency virus) exhibit efficient penetration to the retina after topical delivery Intravitreal injections o Can cause several complications like hemorrhage and retinal displacement o Bevacizumab (Avastin): Used for the treatment of ocular vascularization Adapted from Peptide and Protein Delivery by Chris Van Der Walle

Recently Viewed Presentations

  • 2017 Planned Back to School Spending $30.3 $29.5

    2017 Planned Back to School Spending $30.3 $29.5

    Broadcast Dominates,Cable Under a 1 Rating For Summer. Source: Nielsen NPower (06/26/2017 - 07/23/2017) Live+SD Women 18+ With Children. To be read: Nick's Bubble Guppies had a .51 average rating in July 2017.
  • A Topical Approach to Life-Span Development, 6th edition John ...

    A Topical Approach to Life-Span Development, 6th edition John ...

    Development is observable behavior that we learn through experience with the environment. ... Behavior is strongly influenced by biology, tied to evolution, and characterized by critical or sensitive periods ... A Topical Approach to Life-Span Development, 6th edition John W....
  • You need : A whiteboard pen - Junior Cert Science

    You need : A whiteboard pen - Junior Cert Science

    Anions are negative Cathode is negative. Cations are negative. Cathode Negative Anode Positive Positive ions attracted Negative ions attracted REDUCTION happens here ( positive ions gain electrons) OXIDATION happens here (negative ions lose electrons Uses of Electrolysis Electro-repairing Electrolysis can...
  • Models of the Atom: A Historical perspective

    Models of the Atom: A Historical perspective

    If you divide it is no longer carbon anymore. PIECES OF CARBON CARBON ATOM 1800 -Dalton proposed a modern atomic model based on experimentation not on pure reason His ideas account for the law of conservation of mass (atoms are...
  • The STARFISH Approach to Shrinkage & Engineering

    The STARFISH Approach to Shrinkage & Engineering

    The STARFISH Approach to Shrinkage & Fabric Engineering Shrinkage - Definition Fully Relaxed Dimensions Fully Relaxed Dimensions Reference Dimensions Shrinkage - Variation In General Now Consider This It Follows That Shrinkage Fabric Width Therefore Fabric Area Weight By the way...
  • May 2012 Overuse injuries of the anterior leg

    May 2012 Overuse injuries of the anterior leg

    May 2012 Overuse injuries of the anterior leg in military personnel; literature and Dutch experiences Lt.col Wes Zimmermann MD Royal Dutch Army May 2012, USU/Walter Reed, Washington DC, 60 minutes


    Five score years ago. a great American in whose symbolic shadow we stand today signed the Emancipation Proclamation." This alludes to Abraham Lincoln's Gettysburg Address which began "Four score and seven years ago". As Dr. King mentions in his opening,...
  • AZ Merit Boot Camp 6th Grade Math - Higley Unified School ...

    AZ Merit Boot Camp 6th Grade Math - Higley Unified School ...

    I can write an inequality which has many solutions and represent these solutions on a number line. ... the independent variable goes along the bottom. In an equation, the dependent variable stands alone. 23-34. ... AZ Merit Boot Camp 6th...